Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial

Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, Vienna, Austria.
The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation (Impact Factor: 5.61). 11/2010; 29(11):1218-25. DOI: 10.1016/j.healun.2010.05.016
Source: PubMed

ABSTRACT Third-generation rotary blood pumps have magnetically levitated rotors that eliminate mechanical wear over the years. Together with their potential for miniaturization, these pumps seem suitable for long-term support of patients with a wide range of body surface areas (BSA). Recently, the novel HVAD pump (HeartWare Inc, Framingham, MA), a miniaturized centrifugal pump with a hydrodynamic, magnetically levitated rotor, became ready for clinical application.
In a multi-institutional trial in Europe and Australia, 23 patients (mean age, 47.9 ± 12 years) in end-stage heart failure were enrolled in 5 centers. The primary end point of the bridge-to-transplant study was survival to heart transplant or survival to 180 days on the device, whichever occurred first. Follow-up data at 1 year are presented. The small size of the device allows for intrapericardial placement of the pump.
Implant procedures were generally fast and uneventful. Mean duration of support was 167 ± 143 days (range, 13-425 days), and mean blood flow provided by the pump was 6.1 ± 1.1 liters/min. At the 180-day end point, 2 patients had undergone successful transplant at 157 and 175 days, 2 patients died while on the device, and 19 patients continued pump support for more than 180 days. Actuarial survival after 6 months was 91% and was 86% at the 1-year follow-up.
The design of the HVAD pump enables a quick and less invasive implantation. The results to date demonstrate satisfactory long-term survival with excellent quality of life in this cohort of 23 patients of the initial multi-institutional Conformité Européene (CE) mark trial.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Einleitung Miniaturisierte Herzunterstützungspumpen, sog. Kunstherzsysteme oder „ventricular assist devices“ (VADs) bieten die Möglichkeit, diese Systeme im Kindesalter anzuwenden. Durch die lange Wartezeit auf ein geeignetes Spenderorgan sollte bei Kindern, unterstützt mit einem intrakorporealen VAD, die Entlassung nach Hause angestrebt werden. Schwerpunkte vor einem Spitalaustritt sind neben der adäquaten Schulung und Aufklärung des Patienten und deren Familie auch ein Ausbildungs- und Schulungskonzept für die lokalen Rettungskräfte und die Betreuungspersonen vor Ort. Methoden Es wird ein auf die präklinische Versorgung abgestimmter Notfallalgorithmus für die Erstversorgung von VAD-Patienten vorgestellt sowie das gemeinsam erarbeitete Ausbildungskonzept der lokalen Rettungskräfte und des Kinderspitals Zürich. Schwerpunkte des Schulungsprogramms sind neben der theoretischen Einführung praktische Workshops, „cardiac arrest simulation training“ (CAST) sowie die Erstellung eines genau definierten Alarmierungsplans unter Einbezug der lokalen ärztlichen Organisationsstrukturen und der Spezialisten des Kinderspitals. Schlussfolgerung Die Besonderheiten bei der Versorgung von Kindern am VAD werden vorgestellt und diskutiert.
    Notfall 10/2013; 16(6):469-476. DOI:10.1007/s10049-013-1744-4 · 0.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present report describes the authors' initial experience with implantation of the Heartware left ventricular assist devices (HeartWare Inc., Framingham, MA). via a minimally invasive surgical approach without cardiopulmonary bypass. A detailed overview of the anesthesiologist's role during the procedure, characteristics of the patient population, and short-term clinical outcomes are provided, and the clinical considerations that influence the decision to implant this device via an off-pump minimally invasive approach are outlined. Retrospective medical record review. University hospital. Thirteen patients with advanced heart failure deemed candidates for off-pump minimally invasive left ventricular Heartware implantation as a bridge to heart transplantation. The Heartware left ventricular assist device was implanted in all 13 patients via a minimally invasive approach. One patient required unplanned cardiopulmonary bypass to control bleeding around the left ventricular outflow cannula. The average operating room time was 249.8 minutes±46.2 minutes. Six of 13 patients required no intraoperative red blood cell transfusions. Seven patients were extubated within 12 hours after surgery. Two patients required reintubation within 48 hours. No patients required reoperation for bleeding. Average intensive care unit and hospital lengths of stay were 7.2±3.9 days and 13.4±3.6 days, respectively. There were no in-hospital deaths. Minimally invasive off-pump left ventricular Heartware implantation is an emerging alternative to placement by midline sternotomy. The authors speculate, based on their limited experience, that an off-pump thoracic strategy may be a desirable option for some patients and that clinical outcomes may be non-inferior to placement by midline sternotomy with cardiopulmonary bypass. Copyright © 2015 Elsevier Inc. All rights reserved.
    Journal of Cardiothoracic and Vascular Anesthesia 11/2014; 29(2). DOI:10.1053/j.jvca.2014.11.007 · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart transplantation (HTx) is the treatment of choice for end-stage heart failure but the limited availability of heart's donors still represents a major issue. So long-term mechanical circulatory support (MCS) has been proposed as an alternative treatment option to assist patients scheduled on HTx waiting list bridging them for a variable time period to cardiac transplantation-the so-called bridge-to-transplantation (BTT) strategy. Nowadays approximately 90% of patients being considered for MCS receive a left ventricular assist device (LVAD). In fact, LVAD experienced several improvements in the last decade and the predominance of continuous-flow over pulsatile-flow technology has been evident since 2008. The aim of the present report is to give an overview of continuous-flow LVAD utilization in the specific setting of the BTT strategy taking into consideration the most representative articles of the scientific literature and focusing the attention on the evolution, clinical outcomes, relevant implications on the HTx strategy and future perspectives of the continuous-flow LVAD technology.
    03/2015; 7(3):532-42. DOI:10.3978/j.issn.2072-1439.2015.01.45